Extended Data Fig. 3: Kaplan-Meier Curves for PFS by Investigator Assessment (Final Analysis). | Nature Medicine

Extended Data Fig. 3: Kaplan-Meier Curves for PFS by Investigator Assessment (Final Analysis).

From: Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

Extended Data Fig. 3: Kaplan-Meier Curves for PFS by Investigator Assessment (Final Analysis).

Data cutoff: November 30, 2023; the protocol-specified final analysis of PFS. The 95% CI of median PFS was determined using the Brookmeyer and Crowley method with log-log transformation. HR along with 95% CI was estimated by a stratified Cox proportional hazards model. The P value was calculated by a stratified log-rank test. The exact one-sided P value was 2.9 × 10−14. CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; sac-TMT, sacituzumab tirumotecan.

Back to article page